Voyager Therapeutics, Inc. (NASDAQ:VYGR) shares traded up 15.6% on Wednesday . The company traded as high as $24.25 and last traded at $24.00. 536,635 shares changed hands during trading, an increase of 100% from the average session volume of 267,703 shares. The stock had previously closed at $20.76.
A number of research analysts have recently weighed in on the company. ValuEngine upgraded Voyager Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 30th. Chardan Capital restated a “hold” rating on shares of Voyager Therapeutics in a research note on Sunday, September 10th. Stifel Nicolaus restated a “buy” rating and issued a $33.00 target price on shares of Voyager Therapeutics in a research note on Tuesday, June 27th. BidaskClub upgraded Voyager Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, July 13th. Finally, Zacks Investment Research downgraded Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $24.83.
The company’s 50-day moving average price is $15.46 and its 200 day moving average price is $11.26. The stock’s market cap is $645.67 million.
In other news, insider Bernard Ravina sold 16,470 shares of the firm’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $12.87, for a total value of $211,968.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold a total of 27,450 shares of company stock valued at $321,769 in the last 90 days. 8.00% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Russell Investments Group Ltd. grew its holdings in shares of Voyager Therapeutics by 57.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 11,864 shares of the company’s stock valued at $106,000 after acquiring an additional 4,343 shares in the last quarter. Hershey Trust Co. grew its holdings in shares of Voyager Therapeutics by 163.0% in the 2nd quarter. Hershey Trust Co. now owns 14,394 shares of the company’s stock valued at $129,000 after acquiring an additional 8,921 shares in the last quarter. Oppenheimer & Co. Inc. bought a new position in shares of Voyager Therapeutics in the 2nd quarter valued at about $143,000. Rhumbline Advisers grew its holdings in shares of Voyager Therapeutics by 34.7% in the 2nd quarter. Rhumbline Advisers now owns 16,091 shares of the company’s stock valued at $144,000 after acquiring an additional 4,144 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Voyager Therapeutics by 8.9% in the 2nd quarter. Goldman Sachs Group Inc. now owns 17,048 shares of the company’s stock valued at $153,000 after acquiring an additional 1,399 shares in the last quarter. Institutional investors own 40.70% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.com-unik.info/2017/10/11/voyager-therapeutics-inc-vygr-trading-15-6-higher.html.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
What are top analysts saying about Voyager Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Voyager Therapeutics Inc. and related companies.